<--- Back to Details
First PageDocument Content
Clinical research / Medicine / Antivirals / Therapeutics / United States Public Health Service / Biologic / Center for Biologics Evaluation and Research / Interferon / Validation / Food and Drug Administration / Pharmaceutical sciences / Pharmacology
Clinical research
Medicine
Antivirals
Therapeutics
United States Public Health Service
Biologic
Center for Biologics Evaluation and Research
Interferon
Validation
Food and Drug Administration
Pharmaceutical sciences
Pharmacology

I DEPARTMENT OF HEALTH & HUMAN

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 527,42 KB

Share Document on Facebook

Similar Documents

PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno

DocID: 1vlwz - View Document

IMPORTANT PLEASE READ PART III: CONSUMER INFORMATION INTRON A® interferon alfa-2b This leaflet is part III of a three-part "Product Monograph"

DocID: 1uNBi - View Document

Evaluation of Interferon-gamma-Producing T Cells

DocID: 1uFKZ - View Document

PRODUCT MONOGRAPH INTRON A® interferon alfa-2b Lyophilized Powder with Diluent: 10 million IU interferon alfa-2b/vial

DocID: 1umTG - View Document

  Data Sheet Recombinant Human Interferon-gamma (rh IFN-) Preclinical Grade - Order No.: µg)

DocID: 1u1rK - View Document